MiniMed Type 2 Diabetes Patient Retention Holding Steady, UBS Says

MT Newswires Live

Sep 03

MiniMed's (MMED) diabetes business is showing no meaningful attrition among Type 2 patients, with retention improving across both Type 1 and Type 2 cohorts, UBS said in a note Wednesday.

The company delivered a solid Q1 and also well-positioned for fiscal 2027 with several product launches underway, the firm said.

The bank said roughly 40% of new US pump starts continue to come from Type 2 patients, a trend it attributed to features favored by higher insulin-use patients, including the 300-unit reservoir and 7-day wear on the company's Flex and Fit devices.

The company is transitioning from a pump-only provider to a broader diabetes ecosystem spanning pumps, sensors, smart pens, software and automation, UBS said, pointing to fiscal 2027 as a major product cycle with Flex now shipping, Go continuing to ramp, and Fit and Vivera set to launch during the year.

UBS reiterated a buy rating on the stock and raised its price target to $28 from $25.

Price: 23.53, Change: +1.11, Percent Change: +4.93

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.atigrnest.com/news/2664846415"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2664846415\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2664846415?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-09-03 03:33","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2664846415","market":"nz","top_or_hot":-1,"title":"MiniMed Type 2 Diabetes Patient Retention Holding Steady, UBS Says","media":"MT Newswires Live","content":"<html><body><p> MiniMed's (MMED) diabetes business is showing no meaningful attrition among Type 2 patients, with retention improving across both Type 1 and Type 2 cohorts, UBS said in a note Wednesday.</p><p>The company delivered a solid Q1 and also well-positioned for fiscal 2027 with several product launches underway, the firm said.</p><p>The bank said roughly 40% of new US pump starts continue to come from Type 2 patients, a trend it attributed to features favored by higher insulin-use patients, including the 300-unit reservoir and 7-day wear on the company's Flex and Fit devices.</p><p>The company is transitioning from a pump-only provider to a broader diabetes ecosystem spanning pumps, sensors, smart pens, software and automation, UBS said, pointing to fiscal 2027 as a major product cycle with Flex now shipping, Go continuing to ramp, and Fit and Vivera set to launch during the year.</p><p>UBS reiterated a buy rating on the stock and raised its price target to $28 from $25.</p><p>Price: 23.53, Change: +1.11, Percent Change: +4.93</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>MiniMed Type 2 Diabetes Patient Retention Holding Steady, UBS Says</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMiniMed Type 2 Diabetes Patient Retention Holding Steady, UBS Says\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2026-09-03 03:33</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> MiniMed's (MMED) diabetes business is showing no meaningful attrition among Type 2 patients, with retention improving across both Type 1 and Type 2 cohorts, UBS said in a note Wednesday.</p><p>The company delivered a solid Q1 and also well-positioned for fiscal 2027 with several product launches underway, the firm said.</p><p>The bank said roughly 40% of new US pump starts continue to come from Type 2 patients, a trend it attributed to features favored by higher insulin-use patients, including the 300-unit reservoir and 7-day wear on the company's Flex and Fit devices.</p><p>The company is transitioning from a pump-only provider to a broader diabetes ecosystem spanning pumps, sensors, smart pens, software and automation, UBS said, pointing to fiscal 2027 as a major product cycle with Flex now shipping, Go continuing to ramp, and Fit and Vivera set to launch during the year.</p><p>UBS reiterated a buy rating on the stock and raised its price target to $28 from $25.</p><p>Price: 23.53, Change: +1.11, Percent Change: +4.93</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4198","symbol_name":"医疗保健用品","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2664846415","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2664846415","pubTimestamp":1788377594,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"MiniMed's  diabetes business is showing no meaningful attrition among Type 2 patients, with retention improving across both Type 1 and Type 2 cohorts, UBS said in a note Wednesday.The company delivered a solid Q1 and also well-positioned for fiscal 2027 with several product launches underway, the firm said.The bank said roughly 40% of new US pump starts continue to come from Type 2 patients, a trend it attributed to features favored by higher insulin-use patients, including the 300-unit reservoir and 7-day wear on the company's Flex and Fit devices.The company is transitioning from a pump-only provider to a broader diabetes ecosystem spanning pumps, sensors, smart pens, software and automation, UBS said, pointing to fiscal 2027 as a major product cycle with Flex now shipping, Go continuing to ramp, and Fit and Vivera set to launch during the year.UBS reiterated a buy rating on the stock and raised its price target to $28 from $25.Price: 23.53, Change: +1.11, Percent Change: +4.93","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4198":"医疗保健用品","MMED":"MiniMed Group, Inc."},"translate_title":"瑞银表示，MiniMed 2 型糖尿病患者保留率保持稳定","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"MMED":1},"content_text":"MiniMed's (MMED) diabetes business is showing no meaningful attrition among Type 2 patients, with retention improving across both Type 1 and Type 2 cohorts, UBS said in a note Wednesday.The company delivered a solid Q1 and also well-positioned for fiscal 2027 with several product launches underway, the firm said.The bank said roughly 40% of new US pump starts continue to come from Type 2 patients, a trend it attributed to features favored by higher insulin-use patients, including the 300-unit reservoir and 7-day wear on the company's Flex and Fit devices.The company is transitioning from a pump-only provider to a broader diabetes ecosystem spanning pumps, sensors, smart pens, software and automation, UBS said, pointing to fiscal 2027 as a major product cycle with Flex now shipping, Go continuing to ramp, and Fit and Vivera set to launch during the year.UBS reiterated a buy rating on the stock and raised its price target to $28 from $25.Price: 23.53, Change: +1.11, Percent Change: +4.93","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}